Search clinical trials for: interferons

Total 1115 results

Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety of 24 vs 48 Weeks of Pegetron® (Peginterferon Alfa-2b + Ribavirin) in Naïve Genotype 1 Hepatitis C (Study P05016)(TERMINATED)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)

HIV Infections | Hepatitis C | HCV Infection
Aga Khan University

Unknown

Pegylated Interferon Alone or in Combination With Ezetimibe for Patients With Chronic Hepatitis D

Hepatitis D, Chronic
Merck Sharp & Dohme LLC

Terminated

Study of Response in Chronic Hepatitis C (CHC) Participants Genotype 1 With Insulin Resistance and Prolonged Treatment Duration in Late Responders (P04823/MK-4031-303)

Hepatitis C, Chronic | Insulin Resistance
Merck Sharp & Dohme LLC

Completed

PegIntron Treatment of Chronic Hepatitis B e Antigen-Positive Patients (P05170/MK-4031-327)

Hepatitis B, Chronic
Merck Sharp & Dohme LLC

Completed

PegIntron Versus Adefovir in the Treatment of Chronic Hepatitis B (CHB) e Antigen Positive Patients in Taiwan (P04498/MK-4031-278)

Hepatitis B, Chronic (CHB)
Merck Sharp & Dohme LLC

Terminated

Efficacy of Peginterferon Alfa-2b (SCH 054031) vs Glycyrrhizin in Interferon (IFN)-Treated Patients With Chronic Hepatitis C and F2/F3 Liver Fibrosis (P04773)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Effects of Pegylated Interferon Alfa-2b and Ribavirin After Orthotopic Liver Transplantation in Subjects With Chronic Hepatitis C Recurrence (P04590AM3)(COMPLETED)

Liver Transplantation | Liver Cirrhosis | Hepatitis C, Chronic
Merck Sharp & Dohme LLC
Bioikos Ambiente Srl

Completed

Evaluation of Peginterferon Alfa-2b Monotherapy and Combination With Ribavirin in Participants With Acute Hepatitis C (P03552/MK-4031-137)

Hepatitis C
Merck Sharp & Dohme LLC

Completed

Extended Treatment With PEG-Intron® and Rebetol® in Patients With Genotype 1 Chronic Hepatitis C and Slow Virologic Response (Study P03685)

Hepatitis C, Chronic
Novartis Pharmaceuticals

Completed

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms (Cognition)

Multiple Sclerosis

Italy, Germany
Novartis Pharmaceuticals
Roche Pharma AG

Completed

Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer

Adenocarcinoma | Carcinoma | Renal Cell | Nephroid Carcinoma | Hypernephroid

Belgium, Italy, Spain, United Kingdom, Germany, Taiwan, Turkey, Egypt, Hong Kong, Russian Federation, Switzerland, Thailand, France, Netherlands, Korea, Republic of, Brazil, United States, Czech Republic, South Africa, Hungary, ...
California Cancer Consortium
National Cancer Institute (NCI)

Terminated

Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer

Kidney Cancer

United States
Markus Peck-Radosavljevic
Medical University of Vienna

Completed

Individualized Triple-therapy Using Boceprevir in HIV-positive Patients With Hepatitis C (HIVCOBOC-RGT)

Hepatitis C, Chronic | HIV

Austria
Louis Stokes VA Medical Center

Completed

Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir

Hepatitis C, Chronic | Cirrhosis

United States
Bayer

Completed

Assessment of Strategies for the Management of Flu-like Symptoms in MS Patients Commencing Treatment With Betaferon (INFLUENCE) (INFLUENCE)

Multiple Sclerosis

Poland
Pfizer

Completed

CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder (Null And Partial Responder) Hepatitis C Virus (HCV) Genotype 1 Infected Subjects

Hepatitis, Chronic Active

United States
European Mantle Cell Lymphoma Network
Nordic Lymphoma Group; HOVON - Dutch Haemato-Oncology Association; Lymphoma Study... and other collaborators

Unknown

Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL (MCLelderly)

Lymphoma, Mantle-Cell

Czech Republic, Denmark, France, Germany, Italy, Netherlands, Poland
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC

Completed

Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine

Melanoma

United States
Sunnybrook Health Sciences Centre

Completed

Treatment of Follicular Lymphoma With High Dose Therapy and Stem Cell Support Followed by Rituximab and Alpha Interferon

Follicular Lymphoma

Canada
University of British Columbia
Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma

Completed

Effect of Aerobic Exercise on Side Effects of Disease Modifying Therapy With Subcutaneous Interferon-b1b in Patients With Multiple Sclerosis

Multiple Sclerosis

Canada
Hoffmann-La Roche

Completed

A Study of Pegasys (Peginterferon Alfa-2a) Added to Nucleos(t)Ide Analogue Treatment in Participants With HBeAg-Negative Chronic Hepatitis B Genotype D Showing Stable Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Suppression

Hepatitis B, Chronic

Italy
Biogen

Completed

Tolerability and Quality of Life Study in Participants Who Switched to Avonex Pen (SFERA)

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Clinical Isolated Syndrome (CIS)

Czech Republic, Switzerland
Icahn School of Medicine at Mount Sinai
National Institute on Alcohol Abuse and Alcoholism (NIAAA); Hoffmann-La Roche

Completed

Antiviral & Antifibrotic Liver Therapy in HCV + Drinkers and Non-Drinkers

Hepatitis C

United States
Biogen

Completed

Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017) (ALLOW)

Relapsing Multiple Sclerosis

United States
ANRS, Emerging Infectious Diseases
Bristol-Myers Squibb

Completed

Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)

Hepatitis C Virus Genotype 4 Infection

France
French National Agency for Research on AIDS and...
Merck Sharp & Dohme LLC

Completed

Efficacy of PegInterferon-Ribavirin-Boceprevir Therapy in Patients Infected With G1 HCV With Cirrhosis, Awaiting Liver Transplantation

HCV Infection | Liver Cirrhosis, Experimental

France
EMD Serono

Terminated

RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate (RESOunD)

Multiple Sclerosis

United States
Hoffmann-La Roche

Completed

The Individualized Management With Pegylated-interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Offering Viral Eradication: A Study of Pegylated-interferon Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C (CHC) Non-genotype 2/3 (IMPROVE) (IMPROVE)

Hepatitis C, Chronic

Canada, United States
Biogen

Completed

Long-Term Safety and Efficacy Study of Peginterferon Beta-1a (ATTAIN)

Relapsing Multiple Sclerosis

United States, Croatia, Russian Federation, India, Spain, New Zealand, Canada, Belgium, Netherlands, Bulgaria, Serbia, Greece, Ukraine, Mexico, Georgia, Colombia, Germany, Poland, United Kingdom, Czech Republic, France, Chile, Romania, Eston... and more
National Institute on Drug Abuse (NIDA)
University of Washington

Completed

Treatment of Acute Hepatitis C Virus Infection With Pegylated Interferon in Injection Drug Users

Substance-Related Disorders | Hepatitis

United States
Ronald Hoffman
National Cancer Institute (NCI); Roche Pharma AG; Myeloproliferative Disorders-Research...

Completed

Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)

High Risk Polycythemia Vera | High Risk Essential Thrombocythemia

United States, Italy
Hoffmann-La Roche

Completed

A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies

Renal Cell Carcinoma | Chronic Myelogenous Leukemia | Malignant Melanoma

Canada, India, Bulgaria, Russian Federation, Spain, South Africa, Slovakia
Hanyang University

Unknown

Latent Tuberculosis Infection in Korean Health Care Workers

Latent Tuberculosis

Korea, Republic of
Kaohsiung Medical University Chung-Ho Memorial...

Completed

Tailored Regimens of PEGASYS® and Ribavirin for Genotype 1 Chronic Hepatitis C Patients Trial (TARGET-1)

Hepatitis C

Taiwan
Bristol-Myers Squibb

Completed

Safety Study of BMS-986165 in Healthy Subjects and to Treat Psoriasis

Healthy Subjects

Australia
NYU Langone Health
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Effects of Interferon-Gamma on Cavitary Pulmonary Tuberculosis in the Lungs

Tuberculosis | AIDS-related Complex

United States, South Africa
Hoffmann-La Roche

Terminated

An Observational Study Examining the Use of Triple Combination Therapy With Boceprevir, Peginterferon Alfa-2a and Ribavirin in the Re-Treatment of Chronic Hepatitis C Patients

Hepatitis C, Chronic

Hungary
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Adjuvant Chemoradiotherapy and Interferon Alfa in Treating Patients With Resected Pancreatic Cancer

Pancreatic Cancer

United States
University of British Columbia
Canadian Institutes of Health Research (CIHR)

Completed

Evaluation of a Multi-disciplinary Approach for the Treatment of Hepatitis C in IDUs (HI-LO Study)

Hepatitis C Virus Infection

Canada
Hoffmann-La Roche

Completed

A Retrospective Study to Assess the Impact of the Use of Interferon in Patients With Chronic Hepatitis C (DECISION)

Hepatitis C, Chronic

Brazil
Merck KGaA, Darmstadt, Germany

Completed

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment (SOLAR)

Relapsing-Remitting Multiple Sclerosis

Germany, Estonia, Latvia, Lithuania, Finland, Austria, Denmark, Netherlands, Portugal, Switzerland, Norway, Italy
Novartis
Human Genome Sciences Inc.

Completed

Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C Patients

Chronic Hepatitis C

Taiwan, Germany, Greece, Italy, Spain, United Kingdom, France, Canada, Australia, India, Poland, Thailand
University of North Carolina, Chapel Hill
Tibotec Pharmaceutical Limited

Completed

Differences in Evoked Intracellular Interferon Signaling Pathways Using Single Cell Phosphoprotein Profiling

Hepatitis C

United States
Hoffmann-La Roche

Completed

A Study of Pegylated Interferon Alfa-2a and Lamivudine in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)

Hepatitis B, Chronic

Italy
amfAR, The Foundation for AIDS Research
Kirby Institute

Completed

HCV Treatment in HIV Co-Infected Patients in Asia

Hepatitis C | HIV

Vietnam, Malaysia, Indonesia, Thailand
Emory University
Bayer

Completed

Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation

Leukemia

United States
Peking University People's Hospital

Unknown

Interferon-α After DLI for the Prevention of Relapse (IDPR-HSCT)

Leukemia

China
Peking University People's Hospital

Unknown

Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT

Acute Myeloid Leukemia

China

3

Subscribe